world
Ebola trial testing two drugs begins in Congo outbreak
Patients in Congo’s Ituri province have started receiving experimental treatments in a World Health Organization-sponsored clinical trial. The study will test a monoclonal antibody cocktail and an antiviral drug alongside supportive care for the Bundibugyo strain of Ebola.
thehindubusinessline.comAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
Patients with the Bundibugyo strain of Ebola have started receiving experimental treatments in a clinical trial in Congo’s Ituri province. The World Health Organization-sponsored trial will test Mapp Biopharmaceutical’s monoclonal antibody cocktail MBP134 and Gilead Sciences’s antiviral remdesivir alongside optimized supportive care.
The trial is designed as an adaptive platform study that can continue across future Ebola outbreaks if the current epidemic ends before enough patients are enrolled.
The outbreak has killed more than 500 people in Congo.
Transparency
How sources framed this
These outlets didn't split into competing frames — coverage was uniform.
CorroborationModerate · 2 sources
